The hugely popular medications Ozempic and Wegovy , used for diabetes and weight loss, will be included in the next round of talks to negotiate lower Medicare drug prices.

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Medicare covers Wegovy as a treatment to reduce the risk of serious cardiovascular events in people who have overweight or obesity. It does not cover Wegovy for weight loss.

Millions of Americans would be eligible to have popular drugs used for weight loss like Wegovy or Ozempic covered by Medicare and Medicaid under a rule the Biden administration has proposed.

Key Takeaways Medicare no longer covers Wegovy specifically for weight loss purposes, though coverage may still be available when prescribed for other medical conditions.

Popular weight loss and diabetes drugs like Ozempic and Wegovy have been added to Medicare’s list of medications that will be negotiated directly between the government and drug manufacturers ...

Medicare to negotiate price of Ozempic, Wegovy weight-loss drugs Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

Medicare may cover Wegovy for adults with cardiovascular disease and either obesity or overweight. Learn more about Medicare coverage for Wegovy here.

Ozempic, Wegovy and other drugs are among 15 selected for Medicare’s price negotiations The price negotiations for the additional 15 drugs selected will be handled by the incoming Trump ...

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will be subject to the next round of Medicare price negotiations, the Biden ...

The drug coverage provision does not mention any specific drug by name, but it could include the GLP-1 agonists, such as ...

Together, those 25 drugs account for a third of Medicare spending on prescriptions, Becerra said. Ozempic and Wegovy, in particular, have been scrutinized for their high out-of-pocket costs.